Physician profile
Scott J Schaeffer
NPI 1649242801
$15,704.36
in general payments reported to CMS, 2019-2025
73 companies · $2,583 in 2025
The $2,583 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,913 · 2020: $2,135 · 2021: $2,454 · 2022: $1,734 · 2023: $2,276 · 2024: $2,610 · 2025: $2,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,363 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,363.28 |
| Education | $105.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,734.19 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $1,432.68 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,202.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,001.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $951.07 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $855.20 | 2019-2025 | |
| Astellas Pharma US INC | $742.36 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $695.43 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Gilead Sciences, INC. | $694.71 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $551.18 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $515.54 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Lundbeck LLC | $437.74 | 2022-2025 | Vyepti |
| Janssen Pharmaceuticals, INC | $336.11 | 2020-2025 | Spravato, Xarelto |
| Teva Pharmaceuticals USA, INC. | $269.26 | 2020-2024 | Austedo Xr, Austedo |
| Allergan, INC. | $258.59 | 2019-2020 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schaeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.